We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

International Stem Cell Corp (ISCO) USD0.001

Sell:$0.09 Buy:$0.09 Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.

Contact details

5950 Priestly Dr
United States
+1 (760) 9406383

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
Shares in issue:
8.00 million
Off Exchange
United States
US dollar

Key personnel

  • Andrey Semechkin
    Co-Chairman of the Board, Chief Executive Officer
  • Donald Wright
    Independent Co-Chairman of the Board, CEO and President of SIS, Inc.
  • Russell Kern
    Executive Vice President, Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.